The University of Chicago Header Logo

Connection

Mary Rinella to Humans

Back to Details
This is a "connection" page, showing publications Mary Rinella has written about Humans.
Mary Rinella
Connection Strength
1.680
Humans
  1. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †. Hepatology. 2024 Feb 01; 79(2):E16-E17.
    View in: PubMed
    Score: 0.032
  2. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024 Jan; 65(1):100485.
    View in: PubMed
    Score: 0.032
  3. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Ann Med. 2023 12; 55(1):2211349.
    View in: PubMed
    Score: 0.032
  4. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 Mar 01; 79(3):E93-E94.
    View in: PubMed
    Score: 0.032
  5. Pioneering the path to NASH biomarker approval. Nat Med. 2023 10; 29(10):2416-2417.
    View in: PubMed
    Score: 0.031
  6. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689.
    View in: PubMed
    Score: 0.031
  7. Pegozafermin for NASH - A Sprint to Start a Marathon. N Engl J Med. 2023 Sep 14; 389(11):1044-1046.
    View in: PubMed
    Score: 0.031
  8. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 01; 78(6):1966-1986.
    View in: PubMed
    Score: 0.031
  9. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 12; 79(6):1542-1556.
    View in: PubMed
    Score: 0.031
  10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb; 29(1):101133.
    View in: PubMed
    Score: 0.031
  11. Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92.
    View in: PubMed
    Score: 0.030
  12. Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 Dec 01; 78(6):E103-E104.
    View in: PubMed
    Score: 0.030
  13. Recurrent NAFLD post-LT: Sisyphus' boulder or Proteus' parable? Liver Transpl. 2023 09 01; 29(9):917-918.
    View in: PubMed
    Score: 0.030
  14. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 05 01; 77(5):1797-1835.
    View in: PubMed
    Score: 0.030
  15. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Nonhepatocellular Cancers. Clin Liver Dis. 2023 05; 27(2):251-273.
    View in: PubMed
    Score: 0.030
  16. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterol. 2022 Jul 10; 22(1):335.
    View in: PubMed
    Score: 0.029
  17. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
    View in: PubMed
    Score: 0.028
  18. Fatty Liver Disease: Diagnosis and Stratification. Annu Rev Med. 2022 01 27; 73:529-544.
    View in: PubMed
    Score: 0.027
  19. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 03; 76(3):536-548.
    View in: PubMed
    Score: 0.027
  20. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
    View in: PubMed
    Score: 0.027
  21. Non-alcoholic fatty liver disease. Lancet. 2021 06 05; 397(10290):2212-2224.
    View in: PubMed
    Score: 0.026
  22. Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation. Dig Dis Sci. 2021 01; 66(1):7-9.
    View in: PubMed
    Score: 0.026
  23. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020 12; 73(6):1307-1309.
    View in: PubMed
    Score: 0.025
  24. Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 05; 19(5):1020-1029.e7.
    View in: PubMed
    Score: 0.025
  25. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol. 2020 07; 73(1):9-11.
    View in: PubMed
    Score: 0.025
  26. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 05; 158(7):1851-1864.
    View in: PubMed
    Score: 0.024
  27. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.023
  28. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833.
    View in: PubMed
    Score: 0.023
  29. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol. 2019 04; 114(4):579-590.
    View in: PubMed
    Score: 0.023
  30. Editorial: sarcopenia in liver transplantation-our weakest patients may need the strongest push. Aliment Pharmacol Ther. 2019 04; 49(8):1100-1101.
    View in: PubMed
    Score: 0.023
  31. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol. 2019 04; 70(4):735-744.
    View in: PubMed
    Score: 0.022
  32. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. Obstet Gynecol. 2017 06; 129(6):1118-1123.
    View in: PubMed
    Score: 0.020
  33. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.020
  34. Moderate Exercise for Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2016 08 01; 176(8):1083-4.
    View in: PubMed
    Score: 0.019
  35. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
    View in: PubMed
    Score: 0.019
  36. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2016 May; 61(5):1387-97.
    View in: PubMed
    Score: 0.018
  37. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr; 13(4):196-205.
    View in: PubMed
    Score: 0.018
  38. Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?--In principle yes, in practice not yet. Hepatology. 2016 Mar; 63(3):688-90.
    View in: PubMed
    Score: 0.018
  39. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.018
  40. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015 Dec; 35(12):2575-83.
    View in: PubMed
    Score: 0.018
  41. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015 May; 19(2):361-79.
    View in: PubMed
    Score: 0.017
  42. The "dose" of exercise and its effects beyond weight loss. Hepatology. 2015 Apr; 61(4):1115-7.
    View in: PubMed
    Score: 0.017
  43. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol. 2015 Feb; 12(2):65-6.
    View in: PubMed
    Score: 0.017
  44. Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7.
    View in: PubMed
    Score: 0.016
  45. Interpretation and management of hepatic abnormalities in pregnancy. Clin Gastroenterol Hepatol. 2013 Nov; 11(11):1392-8.
    View in: PubMed
    Score: 0.015
  46. Authors' response. J Acad Nutr Diet. 2013 Feb; 113(2):211-2.
    View in: PubMed
    Score: 0.015
  47. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
    View in: PubMed
    Score: 0.015
  48. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
    View in: PubMed
    Score: 0.014
  49. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
    View in: PubMed
    Score: 0.014
  50. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.014
  51. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.013
  52. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
    View in: PubMed
    Score: 0.012
  53. Primary biliary cirrhosis. Ann Hepatol. 2006 Jul-Sep; 5(3):198-200.
    View in: PubMed
    Score: 0.009
  54. Pregnancy after liver transplantation. Ann Hepatol. 2006 Jul-Sep; 5(3):212-5.
    View in: PubMed
    Score: 0.009
  55. Intensive management of hepatic failure. Semin Respir Crit Care Med. 2006 Jun; 27(3):241-61.
    View in: PubMed
    Score: 0.009
  56. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 May; 9(5):409-410.
    View in: PubMed
    Score: 0.008
  57. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.008
  58. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol Commun. 2024 Feb 01; 8(2).
    View in: PubMed
    Score: 0.008
  59. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228.
    View in: PubMed
    Score: 0.008
  60. Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91.
    View in: PubMed
    Score: 0.008
  61. Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatol Commun. 2024 Jan 01; 8(1).
    View in: PubMed
    Score: 0.008
  62. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024 Mar; 80(3):419-430.
    View in: PubMed
    Score: 0.008
  63. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049.
    View in: PubMed
    Score: 0.008
  64. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease". Hepatology. 2024 Jan 01; 79(1):E5-E6.
    View in: PubMed
    Score: 0.008
  65. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024 Feb 01; 79(2):502-523.
    View in: PubMed
    Score: 0.008
  66. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6.
    View in: PubMed
    Score: 0.008
  67. Fundal variceal bleeding after correction of portal hypertension in patients with cirrhosis. Gastrointest Endosc. 2003 Jul; 58(1):122-7.
    View in: PubMed
    Score: 0.008
  68. A global research priority agenda to advance public health responses to fatty liver disease. J Hepatol. 2023 09; 79(3):618-634.
    View in: PubMed
    Score: 0.008
  69. Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024.
    View in: PubMed
    Score: 0.008
  70. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.008
  71. Research Priorities for Precision Medicine in NAFLD. Clin Liver Dis. 2023 05; 27(2):535-551.
    View in: PubMed
    Score: 0.007
  72. Liver biopsy in living donors. Liver Transpl. 2002 Dec; 8(12):1123-5.
    View in: PubMed
    Score: 0.007
  73. The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. J Gastrointestin Liver Dis. 2022 09 15; 31(3):317-322.
    View in: PubMed
    Score: 0.007
  74. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.007
  75. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022 07; 7(7):603-616.
    View in: PubMed
    Score: 0.007
  76. Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther. 2022 02; 55(4):489-490.
    View in: PubMed
    Score: 0.007
  77. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.007
  78. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022 01; 55(2):234-243.
    View in: PubMed
    Score: 0.007
  79. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 01; 19(1):60-78.
    View in: PubMed
    Score: 0.007
  80. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring). 2021 09; 29(9):1401-1412.
    View in: PubMed
    Score: 0.007
  81. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 09; 44(9):2162-2172.
    View in: PubMed
    Score: 0.007
  82. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
    View in: PubMed
    Score: 0.007
  83. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.
    View in: PubMed
    Score: 0.007
  84. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.007
  85. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol. 2022 09; 20(9):2050-2058.e12.
    View in: PubMed
    Score: 0.007
  86. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
    View in: PubMed
    Score: 0.007
  87. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021 05; 73(5):2028-2038.
    View in: PubMed
    Score: 0.007
  88. From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 2021 03; 73(3):1194-1198.
    View in: PubMed
    Score: 0.006
  89. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021 04; 74(4):972-974.
    View in: PubMed
    Score: 0.006
  90. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):409-418.e5.
    View in: PubMed
    Score: 0.006
  91. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
    View in: PubMed
    Score: 0.006
  92. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 07; 72(1):58-71.
    View in: PubMed
    Score: 0.006
  93. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
    View in: PubMed
    Score: 0.006
  94. Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc. 2020 02 18; 9(4):e014279.
    View in: PubMed
    Score: 0.006
  95. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 04; 158(5):1334-1345.e5.
    View in: PubMed
    Score: 0.006
  96. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 12 14; 394(10215):2184-2196.
    View in: PubMed
    Score: 0.006
  97. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.006
  98. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
    View in: PubMed
    Score: 0.006
  99. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019 12; 34(12):2772-2778.
    View in: PubMed
    Score: 0.006
  100. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Dig Dis Sci. 2019 12; 64(12):3413-3430.
    View in: PubMed
    Score: 0.006
  101. Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug; 51(6):1895-1901.
    View in: PubMed
    Score: 0.006
  102. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019 09; 84:105803.
    View in: PubMed
    Score: 0.006
  103. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
    View in: PubMed
    Score: 0.006
  104. Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. Gastroenterology. 2019 08; 157(2):472-480.e5.
    View in: PubMed
    Score: 0.006
  105. Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. Obesity (Silver Spring). 2019 01; 27(1):59-67.
    View in: PubMed
    Score: 0.006
  106. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940.
    View in: PubMed
    Score: 0.006
  107. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703.
    View in: PubMed
    Score: 0.005
  108. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922.
    View in: PubMed
    Score: 0.005
  109. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.005
  110. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.005
  111. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
    View in: PubMed
    Score: 0.005
  112. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018 06; 47(12):1639-1651.
    View in: PubMed
    Score: 0.005
  113. Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081.
    View in: PubMed
    Score: 0.005
  114. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1.
    View in: PubMed
    Score: 0.005
  115. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018 03 24; 391(10126):1174-1185.
    View in: PubMed
    Score: 0.005
  116. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.005
  117. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
    View in: PubMed
    Score: 0.005
  118. ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management. Gastrointest Endosc. 2017 11; 86(5):757-767.
    View in: PubMed
    Score: 0.005
  119. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.005
  120. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762.
    View in: PubMed
    Score: 0.005
  121. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015 12 17; 1:15080.
    View in: PubMed
    Score: 0.005
  122. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015 Sep; 62(3):773-83.
    View in: PubMed
    Score: 0.004
  123. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.